

Clinical Pharmacy Program Guidelines for DPP-4 Inhibitors- ARIZONA

Program	Prior Authorization
Medication	<p>Preferred Products: Tradjenta (linagliptin), Januvia (sitagliptin), Onglyza (saxagliptin), Kombiglyze XR (saxagliptin/metformin extended release), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin extended-release), Jentadueto (linagliptin/metformin)</p> <p>Non-Preferred Products: alogliptin, alogliptin/metformin, alogliptin/pioglitazone, Jentadueto XR (linagliptin/metformin extended-release)</p>

1. Background:

Janumet and Janumet XR are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin/metformin extended-release is appropriate.

Januvia, Onglyza, and Tradjenta are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Kombiglyze XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.

Alogliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.

Alogliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes in multiple clinical settings when treatment with both alogliptin and metformin is appropriate.

Alogliptin/pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes in multiple clinical settings when treatment with both alogliptin and pioglitazone is appropriate.

Jentadueto and Jentadueto XR are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

2. Coverage Criteria:

A. Tradjenta, Januvia, Onglyza, Kombiglyze XR, Jentadueto, Janumet, Janumet XR

1. The patient has a diagnosis of type 2 diabetes mellitus

-AND-

2. History of failure, intolerance, or contraindication to metformin at a minimum dose of 1500mg daily for 90 days

Authorization will be issued for 12 months.

B. alogliptin, alogliptin/metformin, alogliptin/pioglitazone, Jentadueto XR

1. The patient has a diagnosis of type 2 diabetes mellitus

-AND-

2. History of failure, intolerance, or contraindication to metformin at a minimum dose of 1500mg daily for 90 days

-AND-

3. History of failure, intolerance, or contraindication to three of the following:

- Tradjenta
- Januvia
- Onglyza
- Kombiglyze XR
- Janumet
- Janumet XR
- Jentadueto

Authorization will be issued for 12 months.

3. References:

1. Januvia Prescribing Information. Merck & Co., Inc., April 2012.
2. Janumet Prescribing Information. Merck & Co., Inc., March 2012.
3. Onglyza Prescribing Information. Bristol-Myers Squibb, December 2011.

4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009;32(1):193-203.
5. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract.* 2009;15(6):540-559.
6. Kombiglyze XR Prescribing Information, Bristol-Myers Squibb Company. March 2012.
7. Tradjenta Prescribing Information. Boehringer Ingelheim. July 2011.
8. American Diabetes Association. Standards of medical care in diabetes. *Diabetes Care.* 2011; 34 (suppl 1): S12-S61.
9. Janumet XR Prescribing Information. Merck& Co., Inc., April 2012.
10. American Diabetes Association. Standards of medical care in diabetes. *Diabetes Care.* 2012; 35 (suppl 1): S11-S63.
11. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient centered approach. *Diabetes Care.* 2012, 19 April 2012 [Epub ahead of print]
12. Nesina Prescribing Information. Takeda Pharmaceuticals, Inc., January 2013.
13. Kazano Prescribing Information. Takeda Pharmaceuticals, Inc., January 2013.
14. Oseni Prescribing Information. Takeda Pharmaceuticals, Inc., January 2013.
15. American Diabetes Association. Standards of medical care in diabetes. *Diabetes Care.* 2013; 36 (suppl 1): S11-S66.
16. Jentaducto Prescribing Information. Boehringer Ingelheim. January 2012.
17. AACE Comprehensive Diabetes Management Algorithm, *Endocr Pract.* 2013;19 (No. 2)
18. Jentaducto XR Prescribing Information. Boehringer Ingelheim. January 2012.

Program	Prior Authorization –DPP 4 Inhibitors
Change Control	
Date	Change
August 2017	New policy specific to Arizona.
November 2017	Changed Janumet, Janumet XR and Jentaducto to preferred products